Platelet activation uses a complex set of pathways to respond to vascular injury during hemostasis. However, thrombosis relies on the same set of pathways. Antiplatelet therapies used to prevent thrombotic events often target the P2Y₁₂ platelet receptor for inhibition but can result in bleeding diathesis or in abnormally high ADP...
Platelets undergo morphological changes essential to hemostasis upon activation at sites of vascular injury. The Rho GTPases Rac1, Cdc42, and RhoA drive these changes. Rho guanine nucleotide dissociation inhibitors (RhoGDIs) bind to the Rho GTPases to block the GDP from dissociating from the Rho GTPases, as well as anchoring the...